A feature on Professor Kelly Chibale and H3D has been published in the UK-based Financial Times, one of the world's leading news organisations. The article can be found here: https://www.ft.com/content/c3e47c32-c8c2-11e9-af46-b09e8bfe60c0
The generous donation will be used to establish an initial five-year Neville Isdell Chair in African-centric Drug Discovery and Development at H3D. H3D’s director and founder Professor Kelly Chibale will hold the Chair, which includes the directorship of H3D.
In April 2019 Advanced Courses and Scientific Conferences (ACSC) held a one-week course in South Africa entitled ‘Practical Aspects of Drug Discovery: At the Interface of Biology, Chemistry and Pharmacology’.
June 5, 2019
The US Financial Times recently featured Kelly Chibale as an Innovator in Drug Discovery in Africa
KELLY CHIBALE: LEADING THE WAY IN AFRICAN DRUG DISCOVERY
The rag in Kelly Chibale’s rags-to-riches story is the lit one he used to put into a paraffin-filled tub so that he could study at night. Brought up amid violence and squalor in the Zambian copper belt settlement of Kabulanda — whose name, he says, literally denotes “sadness” — Mr Chibale has fashioned a successful career from a tough start.
UCT’S H3D DIRECTOR, KELLY CHIBALE, WINS SACI GOLD MEDAL AWARD AND IS HONOURED BY ASTMH; WARNS ABOUT THE BRAIN DRAIN OF AFRICAN SCIENTISTS
Professor Kelly Chibale, founder and director of the Drug Discovery and Development Centre, H3D, at the University of Cape Town (UCT), has been awarded the prestigious Gold Medal for 2018 by the South African Chemical Institute (SACI) and honoured by the American Society of Tropical Medicine and Hygiene (ASTMH) with the 2018 Commemorative Fund Lecture.
Prof Kelly Chibale participated in the Bill and Melinda Gates Foundation's Grand Challenges meeting held in Berlin, Germany from 15-18 October 2018 and gave a Spotlight talk.
Drug discovery excellence is a critical prerequisite for success in drug development and remains a highly neglected area for the African continent. The lack of market incentives has biased drug discovery efforts globally away from diseases most prevalent in the developing world. Collaborative efforts of multidisciplinary teams – in drug discovery and other fields – shows that success and efficiency increases significantly when individual contributors combine their complementary capabilities. The whole is greater than the sum of its parts. State-of-the-art approaches to implementing drug discovery projects, especially when the goal is to also build drug discovery capability on the African continent, need to be supported.